analysis

Final outcome analysis from TUXEDO-1 trial is out

Elisa Agostinetto shared a paper by Rupert Bartsch et al. on X:

“Now out the final outcome analysis from TUXEDO-1 trial.

T-DXd in patients with active brain metastases produced prolonged intra and extra cranial disease control.

With 26.5 months median follow-up, mPFS was 21 months and mOS not reached.”

Source: Elisa Agostinetto/X

Elisa Agostinetto is a Clinical Research Fellow at the Institute Jules Bordet in Brussels, Belgium. She is also a Resident in Medical Oncology at Humanitas Research Hospital in Milan, Italy. Agostinetto specializes in Breast Cancer and Immuno-Oncology.

Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab – deruxtecan in. HER2-positive breast cancer patients with active brain metastases.

Authors: Rupert Bartsch, Anna Sophie Berghoff, Julia Furtner, Maximilian Marhold, Elisabeth Sophie Bergen, Sophie Roider-Schur, Maximilian Johannes Mair, Angelika Martina Starzer, Heidrun Forstner, Beate Rottenmanner, Marie-Bernadette Aretin, Karin Dieckmann, Zsuzsanna Bago-Horvath, Helmuth Haslacher, Georg Widhalm, Aysegül Ilhan-Mutlu, Christoph Minichsdorfer, Thorsten Fuereder, Thomas Szekeres, Leopold Oehler, Birgit Gruenberger, Georg Pfeiler, Christian Singer, Ansgar Weltermann, Luzia Berchtold, and Matthias Preusser.

Angelika Martina Starzer Anna Sophie Berghoff Ansgar Weltermann Aysegül Ilhan-Mutlu Beate Rottenmanner Birgit Gruenberger brain metastases cancer Christian Singer Christoph Minichsdorfer cranial disease Elisa Agostinetto Elisabeth Sophie Bergen Georg Pfeiler Georg Widhalm Heidrun Forstner Helmuth Haslacher Julia Furtner Karin Dieckmann Leopold Oehler Luzia Berchtold Marie-Bernadette Aretin Matthias Preusser Maximilian Johannes Mair Maximilian Marhold OncoDaily Oncology Rupert Bartsch Sophie Roider-Schur Thomas Szekeres Thorsten Fuereder TUXEDO-1 trial Zsuzsanna Bago-Horvath